Nitric Oxide in Cancer Therapy

Dear Colleagues,

Our growing understanding of the role of nitric oxide (NO) in cancer biology eventually uncovered its therapeutic potential. Harnessing the pleiotropic anticancer properties of NO represents a promising therapeutic opportunity. For various types of tumor cells, the meaningful role of NO as a sensitizer, by augmenting the effectiveness and/or by overcoming resistance to conventional therapies, has emerged from preclinical and/or clinical research. Although some combinatory strategies (NO-releasing drugs/conventional therapies) demonstrated some clinical benefits, further insights are needed to achieve a successful NO-based therapy regimen for cancer treatment.

This Special Issue of Cells aims to gather recent findings from basic to translational research in the field of NO to contribute to the formaulation of possible new therapeutic strategies for cancer treatment. It will welcome original research articles and review articles covering all relevant aspects of the antitumor spectrum of NO, with an emphasis on potential combinatorial therapeutic strategies:  NO-releasing drugs combined with conventional therapies (chemotherapy, radiotherapy and immunotherapy) or novel anticancer molecules. New insights into the molecular mechanisms of NO events and cellular responses or changes within the tumor microenvironment are of particular interest.  The scope of this Special Issue will address, but is not limited to, cellular signaling involved in tumor cell death and immune responses under the control of NO. The impact of NO on protein function (NO-mediated protein post-translation modifications such as S-nitrosylation, metal-nitrosylation or nitration), technical advancements to improve NO delivery to targeted sites and antitumor efficacy are also key topics.

I look forward to your contributions.

Dr. Stéphanie Plenchette
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• nitric oxide
• cancer
• combined therapy
• sensitization
• tumor microenvironment
• intracellular signaling
• post-translational modifications
• cell death
• immune cells